使用超顺磁性氧化铁 (SPIO) 纳米粒子进行前哨淋巴结 (SLN) 检测已在乳腺癌和前列腺癌中得到广泛研究和标准化，但很少有证据表明其在外阴癌中的应用。本研究的目的是比较在外阴癌患者中使用手术时注射的 SPIO 示踪剂（通过磁力计检测）与使用锝 99 放射性同位素（Tc99）通过伽马探针检测的标准程序进行检测SPIO外阴癌研究是一项SPIO与Tc99相比的单中心前瞻性介入非劣效性研究，于2016年至2021年间在符合外阴癌选择性前哨淋巴结清扫术的GROINSS-V研究纳入标准的患者中进行。包括 18 名患者，总共 41 个 SLN。示踪剂之间的一致性水平为 92.7% (80.6%-97.4%)，对应于 41 个 SLN 中的 38 个，这证实了 SPIO 与 Tc99 相比的非劣效性。使用 Tc99 时每个腹股沟的 SLN 检出率为 96.3 (81.7%-99.3)，使用 SPIO 时为 100% (87.5%-100%)。两种示踪剂对阳性淋巴结的检出率均为100%。使用SPIO作为示踪剂检测外阴癌患者的SLN已被证明不劣于标准放射性示踪剂，具有不需要核磁共振的优点。药物并能够在麻醉诱导后手术时注射。版权所有 © 2024 Elsevier Inc. 保留所有权利。

Sentinel lymph node (SLN) detection with superparamagnetic iron oxide (SPIO) nanoparticles has been widely studied and standardized for breast and prostate cancer, but there is scarce evidence concerning its use in vulvar cancer. The objective of this study was to compare SLN detection using a SPIO tracer injected at the time of the surgery detected by a magnetometer, with the standard procedure of using a technetium 99 radioisotope (Tc99) detected by a gamma probe, in patients with vulvar cancer.The SPIO vulvar cancer study was a single-center prospective interventional non-inferiority study of SPIO compared to Tc99, conducted between 2016 and 2021 in patients who met the GROINSS-V study inclusion criteria for selective sentinel lymph node dissection in vulvar cancer.We included 18 patients and a total of 41 SLNs. The level of agreement between tracers was 92.7% (80.6%-97.4%), corresponding to 38 out of 41 SLNs, which confirms the non-inferiority of SPIO compared to Tc99. The SLN detection rate per groin was 96.3 (81.7%-99.3) using Tc99 and 100% (87.5%-100%) using SPIO. Both tracers had a detection rate of 100% for positive lymph nodes.The use of SPIO as a tracer for detecting SLNs in patients with vulvar cancer has shown to be non-inferior to that of the standard radiotracer, with the advantages of not requiring nuclear medicine and being able to inject it at the time of surgery after induction of anesthesia.Copyright © 2024 Elsevier Inc. All rights reserved.